December 15th, 2015

Company Update (NASDAQ:BIIB): Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016

[Business Wire] – Biogen Inc. today announced it will report fourth quarter and year end 2015 financial results on Wednesday, January 27, 2016, before the financial markets open. Read more on this. Biogen Inc. (BIIB) , currently valued at $66.33B, opened this morning at $294.84. Shares have traded today between $293.50 and $297.86 per share with a one year range of $254.00 to $480.18. BIIB shares are currently priced at 17.70x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.14x earnings multiple for the same period. Consensus earnings for the current quarter by the 20 sell-side analysts covering the stock is an estimate of $4.05 per share, which would be $0.04 worse than the year-ago quarter and a $0.01 sequential increase. The full-year EPS estimate is $16.57 which would be a $2.74 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $2.70 Billion. If reported, that would be a 2.27% increase over the year-ago quarter. Recently, Raymond James Initiated BIIB at Strong Buy (Sep 1, 2015). Previously, H.C. Wainwright Initiated BIIB at to Buy. When considering if the stock is under or overvalued, the average price target is $363.00, which is 23.12% above where the stock opened this morning. See more in (NASDAQ:BIIB) Similar Articles: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – BIIB INVESTORS: The Law Offices of Howard G. Smith Announces An Investigation On Behalf Of Biogen, Inc. Investors Market Update: Biogen Idec Inc (NASDAQ:BIIB) – SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen, Inc. – BIIB Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Douglas Williams to Leave Biogen for Biotechnology Start-Up
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.